Portfolio
The company invests in scientific breakthroughs to improve global health outcomes.
lumagroup.comCrawled Oct 26, 2026
The company invests in scientific breakthroughs to improve global health outcomes.
Biotechnology innovation relies on translating biological insights into therapeutics, diagnostics, and medical devices, with recent advancements driven by AI and machine learning.
Federal funding cuts to agencies like the NSF and NIH threaten early-stage research, potentially delaying scientific progress amid growing competition with China.
Luma Group provides exclusive whitepapers and investment articles on biotech trends, along with a podcast covering AI-powered scientific breakthroughs.
Dr. Themasap Khan discusses his career and the founding of Curve Biosciences with Ritish Patnaik, who shares leadership insights and advice for navigating biotech.
Luma Group finalizes its first life sciences venture capital fund, raising $410 million for long-term investments in biotech startups. The fund targets early-stage companies in the life sciences sector, with commitments spanning over 15 years. This marks a significant milestone for the firm’s inaugural dedicated life sciences fund.
Luma Group closes its first life sciences venture capital fund, **LumaBio Fund I**, raising **$410 million** in committed capital. The fund attracts backing from a global investor base, including sovereign wealth funds, insurance companies, and ultra-high-net-worth individuals. The New York-based firm focuses on investments in life sciences startups and innovations.
Eli Lilly acquires LimmaTech Biologics AG, Curevo Inc., and Vaccine Company, Inc. to strengthen its infectious disease vaccine research. The deals mark a strategic expansion of Lilly’s vaccine development pipeline. The acquired firms specialize in biologics and vaccine technologies, aligning with Lilly’s focus on infectious disease solutions.
Lilly acquires an unnamed vaccine company to develop its Phase 1-ready Epstein-Barr virus (EBV) vaccine candidate. The vaccine targets infectious mononucleosis and long-term conditions linked to EBV infection. Lilly aims to advance this and other infectious disease vaccine programs through the acquisition.
Aeovian Pharmaceuticals secures a $55 million Series B round to advance its lead drug, AV078, through a Phase 2 proof-of-concept study targeting tuberous sclerosis complex (TSC)-related refractory epilepsy. The funding supports clinical development of the biopharmaceutical company’s pipeline in Berkeley, California.